{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:00:04Z","timestamp":1792202404367,"version":"4.4.0"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>Sickle cell disease (SCD) is a genetic disorder predominantly affecting individuals of African descent, with a significant global health burden. SCD is characterized by intravascular hemolysis, driven by the polymerization of mutated hemoglobin within red blood cells (RBCs), leading to vascular inflammation, organ damage, and heme toxicity. Clinical manifestations include acute pain crises, hemolytic anemia, and multi-organ dysfunction, imposing substantial morbidity and mortality challenges. Current therapeutic strategies mitigate these complications by increasing the concentration of RBCs with normal hemoglobin via transfusion, inducing fetal hemoglobin, restoring nitric oxide signaling, inhibiting platelet-endothelium interaction, and stabilizing hemoglobin in its oxygenated state. While hydroxyurea and gene therapies show promise, each faces distinct challenges. Hydroxyurea\u2019s efficacy varies among patients, and gene therapies, though effective, are limited by issues of accessibility and affordability. An emerging frontier in SCD management involves harnessing endogenous clearance mechanisms for hemolysis products. A recent work by Heggland et al. showed that CD-36-like proteins mediate heme absorption in hematophagous ectoparasite, a type of parasite that feeds on the blood of its host. This discovery underscores the need for further investigation into scavenger receptors (e.g., CD36, SR-BI, SR-BII) for their possible role in heme uptake and detoxification in mammalian species. In this review, we discussed current SCD therapeutics and the specific stages of pathophysiology they target. We identified the limitations of existing treatments and explored potential future developments for novel SCD therapies. Novel therapeutic targets, including heme scavenging pathways, hold the potential for improving outcomes and reducing the global burden of SCD.<\/jats:p>","DOI":"10.3389\/fphys.2024.1474569","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T04:57:15Z","timestamp":1726203435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutics for sickle cell disease intravascular hemolysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Jianyao","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-An","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1056\/NEJMoa050460","article-title":"Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease","volume":"353","author":"Adams","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2011-03-325258","article-title":"Fetal hemoglobin in sickle cell anemia","volume":"118","author":"Akinsheye","year":"2011","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/nature11369","article-title":"Structure of the haptoglobin-haemoglobin complex","volume":"489","author":"Andersen","year":"2012","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/s0140-6736(05)78941-8","article-title":"US FDA approves first drug for sickle-cell anaemia","volume":"351","author":"Ault","year":"1998","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/imm.12318","article-title":"Expression and function of endothelial selectins during human development","volume":"143","author":"Auvinen","year":"2014","journal-title":"Immunology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1161\/01.atv.11.6.1700","article-title":"Hemin: a possible physiological mediator of low density lipoprotein oxidation and endothelial injury","volume":"11","author":"Balla","year":"1991","journal-title":"Arterioscler. Thromb."},{"key":"B8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1182\/blood-2013-04-495887","article-title":"Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease","volume":"123","author":"Belcher","year":"2014","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"H2715","DOI":"10.1152\/ajpheart.00986.2004","article-title":"Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice","volume":"288","author":"Belcher","year":"2005","journal-title":"Am. J. Physiol-Heart C"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1172\/JCI104410","article-title":"The effect of methemoglobin formation in sickle cell disease","volume":"40","author":"Beutler","year":"1961","journal-title":"J. Clin. Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1182\/blood.v46.2.253.bloodjournal462253","article-title":"The effect of carbon monoxide on red cell life span in sickle cell disease","volume":"46","author":"Beutler","year":"1975","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bolanos-Meade","year":"2012","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/jcla.10070","article-title":"Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy","volume":"17","author":"Borba","year":"2003","journal-title":"J. Clin. Lab. Anal."},{"key":"B14","doi-asserted-by":"publisher","first-page":"192-+","DOI":"10.1038\/nature15521","article-title":"Enhancer dissection by Cas9-mediated in situ saturating mutagenesis","volume":"527","author":"Canver","year":"2015","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.58347\/tml.2024.1694a","article-title":"Casgevy and Lyfgenia: two gene therapies for sickle cell disease","volume":"66","year":"2024","journal-title":"Med. Lett. Drugs Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/bloodadvances.2019001143","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support","volume":"4","author":"Chou","year":"2020","journal-title":"Blood Adv."},{"key":"B17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/0002-9343(55)90208-4","article-title":"The metabolism of hemoglobin and bile pigment in hemolytic disease","volume":"18","author":"Crosby","year":"1955","journal-title":"Am. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.bbmt.2013.02.010","article-title":"Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease","volume":"19","author":"Dallas","year":"2013","journal-title":"Biol. Blood Marrow Tr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/bloodadvances.2022007802","article-title":"Venous thromboembolism prophylaxis in sickle cell disease: a multicenter cohort study of adolescent inpatients","volume":"7","author":"Davila","year":"2023","journal-title":"Blood Adv."},{"key":"B20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1401731","article-title":"Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia","volume":"371","author":"DeBaun","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI20986","article-title":"Central role of the P2Y12 receptor in platelet activation","volume":"113","author":"Dorsam","year":"2004","journal-title":"J. Clin. Invest"},{"key":"B22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/s0741-5214(97)70211-8","article-title":"Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis","volume":"25","author":"Downing","year":"1997","journal-title":"J. Vasc. Surg."},{"key":"B23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fphar.2014.00115","article-title":"Heme on innate immunity and inflammation","volume":"5","author":"Dutra","year":"2014","journal-title":"Front. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1182\/blood-2017-02-765891","article-title":"Treating sickle cell disease by targeting HbS polymerization","volume":"129","author":"Eaton","year":"2017","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1161\/STROKEAHA.115.011956","article-title":"Heme-hemopexin scavenging is active in the brain and associates with outcome after subarachnoid hemorrhage","volume":"47","author":"Garland","year":"2016","journal-title":"Stroke"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S398","DOI":"10.1016\/j.amepre.2011.09.013","article-title":"Sickle cell disease in Africa: a neglected cause of early childhood mortality","volume":"41","author":"Grosse","year":"2011","journal-title":"Am. J. Prev. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1182\/blood-2010-05-285718","article-title":"Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease","volume":"117","author":"Gutsaeva","year":"2011","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000307","article-title":"Indications for transfusion in the management of sickle cell disease","author":"Han","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/phar.2409","article-title":"Systematic review of Crizanlizumab: a new parenteral option to reduce vaso-occlusive pain crises in patients with sickle cell disease","volume":"40","author":"Han","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2215\/CJN.08511109","article-title":"Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature","volume":"5","author":"Haymann","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1038\/s41598-019-40590-x","article-title":"A scavenger receptor B (CD36)-like protein is a potential mediator of intestinal heme absorption in the hematophagous ectoparasite Lepeophtheirus salmonis","volume":"9","author":"Heggland","year":"2019","journal-title":"Sci. Rep-Uk"},{"key":"B33","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1073\/pnas.1922004117","article-title":"Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease","volume":"117","author":"Henry","year":"2020","journal-title":"P Natl. Acad. Sci. U. S. A."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1182\/blood.2021012070","article-title":"Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin","volume":"138","author":"Henry","year":"2021","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1182\/blood-2005-03-1185","article-title":"Identification of the receptor scavenging hemopexin-heme complexes","volume":"106","author":"Hvidberg","year":"2005","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/ijns5020020","article-title":"Sickle cell disease-genetics, pathophysiology, clinical presentation and treatment","volume":"5","author":"Inusa","year":"2019","journal-title":"Int. J. Neonatal Screen"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s40273-021-01072-z","article-title":"The use of cost-effectiveness analysis in sickle cell disease: a critical review of the literature","volume":"39","author":"Jiao","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"113461","DOI":"10.1016\/j.expneurol.2020.113461","article-title":"The effect of type 2 diabetes on CD36 expression and the uptake of oxLDL: diabetes affects CD36 and oxLDL uptake","volume":"334","author":"Kanoke","year":"2020","journal-title":"Exp. Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B40","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1172\/JCI89741","article-title":"Intravascular hemolysis and the pathophysiology of sickle cell disease","volume":"127","author":"Kato","year":"2017","journal-title":"J. Clin. Invest"},{"key":"B41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1172\/JCI17597","article-title":"A role for nitric oxide in hydroxyurea-mediated fetal hemoglobin induction","volume":"111","author":"King","year":"2003","journal-title":"J. Clin. Investigation"},{"key":"B42","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/35051594","article-title":"Identification of the haemoglobin scavenger receptor","volume":"409","author":"Kristiansen","year":"2001","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1089\/ars.2016.6954","article-title":"Red blood cell function and dysfunction: redox regulation, nitric oxide metabolism, anemia","volume":"26","author":"Kuhn","year":"2017","journal-title":"Antioxid. Redox Signal"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1182\/blood-2023-188639","article-title":"Safety profile of Crizanlizumab 5.0 Mg\/kg in sickle cell disease: pooled data from clinical trials","volume":"142","author":"Kutlar","year":"2023","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"113","DOI":"10.12688\/f1000research.9970.1","article-title":"Recent advances in (therapeutic protein) drug development","volume":"6","author":"Lagasse","year":"2017","journal-title":"F1000Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1182\/blood-2005-10-009506","article-title":"Stroke prevention trial in sickle cell anemia (STOP): extended follow-up and final results","volume":"108","author":"Lee","year":"2006","journal-title":"Blood"},{"key":"B47","first-page":"21","volume":"60","year":"2018","journal-title":"Med. Lett. Drugs Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood.v92.6.1870","article-title":"Increased susceptibility in Hp knockout mice during acute hemolysis","volume":"92","author":"Lim","year":"1998","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e2012065","DOI":"10.4084\/MJHID.2012.065","article-title":"Sickle cell anaemia and malaria","volume":"4","author":"Luzzatto","year":"2012","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1161\/01.cir.102.16.1931","article-title":"P-selectin expression on platelets determines size and stability of platelet aggregates","volume":"102","author":"Merten","year":"2000","journal-title":"Circulation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJMe1800976","article-title":"L-glutamine and the dawn of combination therapy for sickle cell disease","volume":"379","author":"Minniti","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood.v32.5.811.811","article-title":"Brief report: plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases","volume":"32","author":"Muller-Eberhard","year":"1968","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1056\/NEJMsa063904","article-title":"Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development","volume":"355","author":"Murad","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/genes12071096","article-title":"Hydroxyurea-the good, the bad and the ugly","volume":"12","author":"Musialek","year":"2021","journal-title":"Genes-Basel"},{"key":"B55","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/ajcp\/56.2.137","article-title":"Plasma hemoglobin and hemoglobin fractions in sickle cell crisis","volume":"56","author":"Naumann","year":"1971","journal-title":"Am. J. Clin. Pathol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e174575","DOI":"10.1172\/jci.insight.174575","article-title":"High-mobility group box 1 increases platelet surface P2Y12 and platelet activation in sickle cell disease","volume":"9","author":"Nolfi-Donegan","year":"2024","journal-title":"JCI Insight"},{"key":"B58","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.trsl.2015.07.001","article-title":"Inflammatory targets of therapy in sickle cell disease","volume":"167","author":"Owusu-Ansah","year":"2016","journal-title":"Transl. Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e1775","DOI":"10.1542\/peds.2014-2986","article-title":"Evidence-based management of sickle cell disease: expert Panel report, 2014","volume":"134","author":"Panel","year":"2014"},{"key":"B60","doi-asserted-by":"publisher","first-page":"103060","DOI":"10.1016\/j.transci.2021.103060","article-title":"CRISPR\/Cas9 gene editing for curing sickle cell disease","volume":"60","author":"Park","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"B61","article-title":"Management of sickle cell disease","author":"Physicians","year":"2023"},{"key":"B62","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2013","journal-title":"Lancet"},{"key":"B63","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/515S2a","article-title":"Epidemiology: a moving target","volume":"515","author":"Pleasants","year":"2014","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2018-03-834440","article-title":"L-Glutamine for sickle cell anemia: more questions than answers","volume":"132","author":"Quinn","year":"2018","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/bjh.15115","article-title":"How I manage red cell transfusions in patients with sickle cell disease","volume":"180","author":"Rees","year":"2018","journal-title":"Br. J. Haematol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/1535370219900637","article-title":"L-glutamine for sickle cell disease: knight or pawn?","volume":"245","author":"Sadaf","year":"2020","journal-title":"Exp. Biol. Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1182\/blood.2020005134","article-title":"Heme A1M'ed at the kidney in sickle cell disease","volume":"135","author":"Saraf","year":"2020","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03790.x","article-title":"Induction of the CD163-dependent haemoglobin uptake by macrophages as a novel anti-inflammatory action of glucocorticoids","volume":"119","author":"Schaer","year":"2002","journal-title":"Brit J. Haematol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1182\/blood-2012-11-451229","article-title":"Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins","volume":"121","author":"Schaer","year":"2013","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1182\/blood-2005-03-1014","article-title":"CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin","volume":"107","author":"Schaer","year":"2006","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3389\/fphys.2014.00415","article-title":"Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development","volume":"5","author":"Schaer","year":"2014","journal-title":"Front. Physiol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1182\/blood-2008-04-078188","article-title":"Hemoglobin research and the origins of molecular medicine","volume":"112","author":"Schechter","year":"2008","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.3109\/10428194.2014.893310","article-title":"Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory\/resistant to hydroxyurea","volume":"55","author":"Sever","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","article-title":"A trial of unrelated donor marrow transplantation for children with severe sickle cell disease","volume":"128","author":"Shenoy","year":"2016","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fphys.2015.00187","article-title":"Hemopexin and haptoglobin: allies against heme toxicity from hemoglobin not contenders","volume":"6","author":"Smith","year":"2015","journal-title":"Front. Physiol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1164\/rccm.201002-0223OC","article-title":"Inhibition of neutrophil migration by hemopexin leads to increased mortality due to sepsis in mice","volume":"183","author":"Spiller","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1100\/tsw.2008.157","article-title":"Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches","volume":"8","author":"Steinberg","year":"2008","journal-title":"ScientificWorldJournal"},{"key":"B80","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/87551225211008460","article-title":"Crizanlizumab for the prevention of vaso-occlusive pain crises in sickle cell disease","volume":"37","author":"Stevens","year":"2021","journal-title":"J. Pharm. Technol."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1161\/atvb.42.suppl_1.423","article-title":"Abstract 423: imatinib promotes reverse cholesterol transport and elevates Sr-bi","volume":"42","author":"Sucharski","year":"2022","journal-title":"Arter. Throm Vas"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1006\/cyto.2000.0720","article-title":"Human monocytes express CD163, which is upregulated by IL-10 and identical to p155","volume":"12","author":"Sulahian","year":"2000","journal-title":"Cytokine"},{"key":"B83","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/01.NAJ.0000559779.40570.2c","article-title":"CE: understanding the complications of sickle cell disease","volume":"119","author":"Tanabe","year":"2019","journal-title":"Am. J. Nurs."},{"key":"B84","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1182\/blood-2002-04-1270","article-title":"Enhanced splenomegaly and severe liver inflammation in haptoglobin\/hemopexin double-null mice after acute hemolysis","volume":"100","author":"Tolosano","year":"2002","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1182\/blood.v94.11.3906","article-title":"Defective recovery and severe renal damage after acute hemolysis in hemopexin-deficient mice","volume":"94","author":"Tolosano","year":"1999","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","first-page":"9","DOI":"10.58347\/tml.2024.1694a","article-title":"Casgevy and Lyfgenia: two gene therapies for sickle cell disease","volume":"66","year":"2024","journal-title":"Med. Lett. Drugs Ther."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1182\/blood.2022015596","article-title":"Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics","volume":"140","author":"Vallelian","year":"2022","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41581-019-0181-0","article-title":"Mechanisms of haemolysis-induced kidney injury","volume":"15","author":"Van Avondt","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1182\/blood.v98.6.1802","article-title":"Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase","volume":"98","author":"Wagener","year":"2001","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia-TCD with Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial","volume":"387","author":"Ware","year":"2016","journal-title":"Lancet"},{"key":"B92","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.1038\/s41467-022-33349-y","article-title":"CD36-mediated metabolic crosstalk between tumor cells and macrophages affects liver metastasis","volume":"13","author":"Yang","year":"2022","journal-title":"Nat. Commun."},{"key":"B93","doi-asserted-by":"publisher","first-page":"S536","DOI":"10.1016\/j.amepre.2010.01.001","article-title":"Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999-2007","volume":"38","author":"Yusuf","year":"2010","journal-title":"Am. J. Prev. Med."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2024.1474569\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T04:57:20Z","timestamp":1726203440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2024.1474569\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":93,"alternative-id":["10.3389\/fphys.2024.1474569"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2024.1474569","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"article-number":"1474569"}}